EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

Kyle Arsenault-Mehta, Mario Hochman-Bérard, Alexander Johnson, Dar'ya Semenova, Bea Nguyen, Jessie Willis, Natalia Mouravska, Ridha Joober, Naista Zhand iD

Neuropsychopharmacology Reports · 2024

DOI: 10.1002/npr2.12382 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Kyle Arsenault-Mehta und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Ottawa Mental Health Center, The University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Schizophrenia, Cognitive Dysfunction, Cognition Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cognitive impairment are among the core features of schizophrenia, experienced by up to 75% of patients. Available treatment options for schizophrenia including dopamine antagonists and traditional antipsychotic medications have not been shown to confer significant benefits on cognitive deficits. Contrary to the focus on management of positive symptoms in schizophrenia, cognitive abilities are main predictor of independent living skills, functional abilities, employment, engagement in relapse prevention, and patients' subjective sense of well‐being and quality of life. This review aims to provide a summary of recent literature on pharmacological options for the treatment of cognitive deficits in schizophrenia.

Methods

We conducted a literature search of studies from 2011 to 2021 across four electronic databases including PubMed, PsycInfo, MEDLINE, and Embase. Human studies using a pharmacological treatment for cognitive impairment in schizophrenia were included.

Results

Fifty‐eight eligible publications, representing 11 pharmacological classes, were included in this review. Major limitations involved small sample size, methodological limitations as well as heterogeneity of participants and outcome measures.

Conclusions

Overall evidence remains inconclusive for any pharmacological classes studied for the treatment of cognitive deficits in schizophrenia. Methodological limitations in a majority of the studies rendered their findings preliminary. We further discuss possible explanations for these findings that could guide future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaCognitive DysfunctionCognition DisordersHumansQuality of LifeCognition

Stichwörter der Autor:innen

cognitioncognitive dysfunctionneuropharmacologypsychopharmacologyschizophrenia

Autor:innen und Institutionen

  • The Royal Ottawa Mental Health Center, The University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
  • The University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
  • Department of Psychiatry, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Naista Zhand

Zitieren

APA

Arsenault-Mehta, K., Hochman-Bérard, M., Johnson, A., Semenova, D., Nguyen, B., Willis, J., Mouravska, N., Joober, R., & Zhand, N. (2024). Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12382

Vancouver

Arsenault-Mehta K, Hochman-Bérard M, Johnson A, Semenova D, Nguyen B, Willis J, et al. Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12382

BibTeX
@article{ArsenaultMehta2024,
  author = {Arsenault-Mehta, Kyle and Hochman-Bérard, Mario and Johnson, Alexander and Semenova, Dar'ya and Nguyen, Bea and Willis, Jessie and Mouravska, Natalia and Joober, Ridha and Zhand, Naista},
  title = {Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review},
  journal = {Neuropsychopharmacology Reports},
  year = {2024},
  doi = {10.1002/npr2.12382}
}
Kostenlos starten →